Effects of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension

Summary

In this multicenter, randomized, placebo-controlled trial in pre-heat failure patients with hypertension and without diabetes, we will enroll 120 eligible patients to randomized to receive placebo or engagliflozin (10mg/d) for follow them for 6 months. The primary endpoint is the left atrial volume index, which reflects left ventricular diastolic function. We sought to comprehensively evaluate the effect of engagliflozin on the structure and function and explore its underlying mechanisms.

Timeline

Start

2024-01-19

Primary completion

2026-12-31

Completion

2026-12-31

Drugs

Indications